Additionally, subtype strategies using clinical, biomarker and transcriptomic data do not identify comparable patient populations with sepsis (117), suggesting precision medicine approaches to identifying which patients might respond to AMPK-targeted therapies would be challenging. Here, PRKAA1 is linked to Sepsis.